Curis Inc logo

CRIS

Curis Inc

$1.3

Earnings Summary

Revenue
$2.39Mn
Net Profits
$-15.94Mn
Net Profit Margins
-666.11%

Highlights

Revenue:

Curis Inc’s revenue jumped 4.68% since last year same period to $2.39Mn in the Q2 2022. On a quarterly growth basis, Curis Inc has generated 16.33% jump in its revenue since last 3-months.

Net Profits:

Curis Inc’s net profit fell -47.08% since last year same period to $-15.94Mn in the Q2 2022. On a quarterly growth basis, Curis Inc has generated 1.05% jump in its net profits since last 3-months.

Net Profit Margins:

Curis Inc’s net profit margin fell -40.5% since last year same period to -666.11% in the Q2 2022. On a quarterly growth basis, Curis Inc has generated 14.94% jump in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Curis Inc post its latest quarter earnings

EPS Estimate Current Quarter
-0.17
EPS Estimate Current Year
-0.17

Highlights

EPS Estimate Current Quarter:

Curis Inc’s earning per share (EPS) estimates for the current quarter stand at -0.17 - a -6.25% fall from last quarter’s estimates.

EPS Estimate Current Year:

Curis Inc’s earning per share (EPS) estimates for the current year stand at -0.17.

Key Ratios

Key ratios of the Curis Inc post its Q2 2022 earnings

Return on Assets (ROA)
-0.21
Return on Equity (ROE)
-0.65
Dividend Per Share (DPS)
0

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Curis Inc’s return on assets (ROA) stands at -0.21.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Curis Inc’s return on equity (ROE) stands at -0.65.

Dividend Per Share (DPS):

Curis Inc declared 0 dividend per share during the earnings announcement for Q2 2022.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-05-05
-0.16
-0.18
-12.5%

Company Information

Curis is a biotechnology company focused on the development of innovative therapeutics for the treatment of cancer. In 2015, Curis entered into a collaboration with Aurigene in the areas of immuno-oncology and precision oncology. As part of this collaboration, Curis has exclusive licenses to oral small molecule antagonists of immune checkpoints including the VISTA/PDL1 antagonist CA-170, and the TIM3/PDL1 antagonist CA-327, as well as the IRAK4 kinase inhibitor, CA-4948. CA-4948 is currently undergoing testing in a Phase 1 in patients with non-Hodgkin's lymphoma both as a monotherapy and in combination the with BTK inhibitor ibrutinib. Curis is also evaluating CA-4948 in a Phase 1 trial in patients with acute myeloid leukemia and myelodysplastic syndromes. In addition, Curis is engaged in a collaboration with ImmuNext for development of CI-8993, a monoclonal anti-VISTA antibody, which is currently undergoing testing in a Phase 1a/1b trial in patients with solid tumors. Curis is also party to a collaboration with Genentech, a member of the Roche Group, under which Genentech and Roche are commercializing Erivedge® for the treatment of advanced basal cell carcinoma.

Organisation
Curis Inc
Headquarters
Lexington, Massachusetts, US
Employees
28
Industry
Health Technology
CEO
James Dentzer